Lonza Sells Particle Size Reduction Facility
The firm announced it entered into a deal to divest the Quakertown, PA location to a group of investors.
May 6, 2022
Pharmaceutical and biotech manufacturer Lonza struck a deal to sell its particle size reduction facility in Quakertown, PA to a group of investors for undisclosed terms.
The location houses two buildings and supporting infrastructure – including nine cGMP suites, two development suites, and phase-appropriate equipment from development to commercial supply. Lonza’s operations focus on particulate size reduction and control services for drug substances and excipients.
Following the acquisition, the business will be rebranded as Microsize led by investors Derek Hennecke and TJ Higley.
“With the industry experience and knowledge of the Quakertown business, the team is the ideal buyer to build on the site’s two decades of experience with particle size control technologies,” said Christian Dowdeswell, vice president and head of commercial development, Small Molecules for Lonza, in a recent company release. “As the business begins a new chapter, we are confident that the site’s capabilities in milling and micronization will be of great advantage to Microsize’s offering.”
Financial terms of the transaction were not revealed. Lonza said it will continue to provide micronization and jet milling services at its Monteggio site under its Particle Engineering suite of services.
“Microsize will have a dedicated focus on delivering the best particle size reduction solution for the smallest biotech company all the way through the largest pharmaceutical businesses. We have gathered a team of experienced CDMO investors, such as Mark Bamforth, founder of Brammer Bio and Arranta Bio, and Bill Mitchell, the founder of PCI Pharma Services, to provide much more than financial capacity,” Hennecke and Higley, said in a statement. “All of our investors come from the CDMO industry and will be active in its support.”
About the Author
You May Also Like